Back

Implementation of high-sensitivity cardiac troponin and risk of myocardial infarction or death at 5 years: a stepped-wedge cluster-randomised controlled trial

26 August 2022 (14:40 - 14:50)
Organised by:
Congress Presentation Part of: Troponin and other biomarkers in acute coronary syndromes Biomarkers ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Kuan Ken Lee

University of Edinburgh, Edinburgh (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Extending the no objective testing rules to patients triaged by the ESC 0/1-hour algorithms
Doctor J. Boeddinghaus (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Cardiac troponin elevation and mortality in takotsubo syndrome: new insights from the international takotsubo (InterTAK) registry
Professor B. Stahli (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Impact of time from symptom onset on the diagnostic performance of high-sensitivity cardiac troponin for type 1 myocardial infarction
Doctor M. Lowry (Edinburgh, GB)
Abstract Slides Video
Presentation thumbnail
High-sensitivity troponin is a biomarker of medium term mortality in 20,000 consecutive hospital patients undergoing a blood test for any reason
Doctor J. Hinton (Bournemouth, GB)
Abstract Slides Video
Presentation thumbnail
Prognostic importance of NT-proBNP following high-risk myocardial infarction in the PARADISE-MI Trial
Doctor K. Jering (Boston, US)
Abstract Slides Video

Access the full session

Session thumbnail
Troponin and other biomarkers in acute coronary syndromes

The Event

Event poster

ESC Congress 2022

26 August 2022 14:40 CET
You may be interested in
thumbnail
Congress Presentation
Impact of switching high-sensitivity cardiac troponin assays on risk stratification in suspected acute coronary syndrome
thumbnail
Congress Presentation
Comparison of conventional and high sensitive cardiac troponin in pulmonary embolism risk assessement
thumbnail
Congress Presentation
Cardiac biomarkers in cardiovascular risk assessment: state of the art

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources